Lengo Therapeutics is a biopharmaceutical company focused on the discovery and development of targeted therapies for cancer using advanced drug discovery techniques. The company aims to create effective treatments that improve patient outcomes by addressing the underlying mechanisms of oncological diseases.
Funding
$1.3B raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers are driven by specific genetic mutations that lead to uncontrolled cell growth and proliferation. Traditional cancer treatments often lack the precision to target these underlying genetic drivers, resulting in limited efficacy and significant side effects. There is a need for therapies that can selectively inhibit the activity of mutated proteins to improve patient outcomes.
Solution
Blueprint Medicines is a biopharmaceutical company focused on developing targeted kinase inhibitors for genomically defined cancers, allergic/inflammatory diseases and other disorders. The company's approach involves identifying the specific genetic alterations that drive disease and designing small-molecule drugs to selectively inhibit the activity of the corresponding mutated kinases. By targeting the root causes of disease, Blueprint Medicines aims to develop more effective and personalized therapies with improved safety profiles. Their pipeline includes multiple clinical-stage programs focused on various cancers and mast cell disorders.
Target Audience
The primary target audience includes patients with genomically defined cancers and allergic/inflammatory diseases, as well as medical professionals specializing in oncology, hematology, and immunology.
Features
- Development of selective kinase inhibitors targeting specific genetic mutations
- Focus on genomically defined cancers and allergic/inflammatory diseases
- Clinical-stage programs for systemic mastocytosis, GIST, breast cancer, and urticaria
- Avapritinib: Approved for adults with advanced systemic mastocytosis, indolent systemic mastocytosis, and GIST harboring a PDGFRA exon 18 mutation
- Elenestinib: Under development for indolent and advanced systemic mastocytosis
- BLU-808: Planned development for chronic spontaneous and inducible urticaria and other mast cell-mediated diseases
- BLU-222: Development programs for hormone-receptor-positive, HER2-negative metastatic breast cancer and other CDK2-vulnerable cancers